Eli Lilly was among the investors in neurodegenerative disease drug developer Vanqua Bio’s $85m series B round.
Vanqua Bio, a US-based developer of treatments for neurodegenerative diseases, emerged from stealth yesterday with $85m in series B funding from investors including pharmaceutical firm Eli Lilly. Omega Funds led the round, which also featured OrbiMed, Surveyor Capital, Avoro Ventures, Casdin Capital, Pontifax, Osage University Partners and Logos Capital. Founded in 2019 as Surmount Bio,…
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.